Smith & Nephew 

$30.46
595
-$0.11-0.36% 今天

統計

當日最高
30.79
當日最低
30.35
52週高點
38.79
52週低點
28.4
成交量
645,086
平均成交量
1,085,698
市值
0
本益比
21.38
股息殖利率
2.57%
股息
0.78

即將到來

股息

2.57%股息殖利率
May 26
$0.48
Nov 25
$0.30
May 25
$0.46
Nov 24
$0.29
May 24
$0.46
10年成長
2.25%
5年成長
0.84%
3年成長
1.4%
1年成長
2.62%

財報

4Aug預期
Q4 2023
Q1 2024
Q2 2024
Q4 2024
Q2 2025
Q4 2025
下一步
0
0.2
0.39
0.59
預期EPS
0.4675
實際EPS
不適用

財務

7.09%利潤率
有盈利
2019
2020
2021
2022
2023
2024
5.81B營收
412M淨利

分析師評級

30.00平均目標價
最高預估為 30.00。
來自過去6個月內的 1 則評分。這不是投資建議。
買入
0%
持有
100%
賣出
0%

其他人也在關注

此清單是根據在 Stock Events 上追蹤 SNN 的使用者自選建立的。這不是投資建議。

競爭對手

此清單為基於近期市場事件的分析。並非投資建議。

關於

Smith & Nephew plc, along with its various subsidiary companies, operates globally in the research, development, manufacturing, marketing, and distribution of medical devices. The company's orthopedic reconstruction portfolio includes knee implants designed for total knee replacement surgeries and hip implants used in the reconstruction of hip joints. Additionally, they provide trauma and extremity products, which encompass both internal and external fixation devices essential for stabilizing severe bone fractures and correcting skeletal deformities. For surgical practitioners, Smith & Nephew develops sports medicine joint repair solutions. These offerings feature specialized instruments, advanced technologies, and implants crucial for performing minimally invasive procedures on joints. Such procedures address a range of issues, including soft tissue injuries and degenerative conditions affecting the knee, hip, and shoulder, as well as providing systems for meniscal repair. Furthermore, the company supplies arthroscopic enabling technologies. These consist of fluid management systems for surgical access, high-definition cameras, digital image capture devices, endoscopes, light sources, and monitors, all designed to offer enhanced visualization within joints. They also provide radiofrequency, electromechanical, and mechanical tools for tissue resection, alongside hand instruments for the removal of damaged tissue. Additionally, Smith & Nephew offers ear, nose, and throat (ENT) solutions. In the realm of wound management, Smith & Nephew provides an extensive range of advanced wound care products intended for both the treatment and prevention of acute and chronic wounds. This category covers conditions such as leg, diabetic, and pressure ulcers, burns, and post-operative wounds. Their advanced wound bioactives division includes biologics and other biologically active technologies vital for debridement and promoting dermal repair and regeneration. This also extends to regenerative medicine products, such as substitutes for skin, bone grafts, and articular cartilage. Completing their wound care offerings are advanced wound devices, including traditional and single-use negative pressure wound therapy systems and hydrosurgery systems. The primary customer base for Smith & Nephew plc consists of healthcare providers worldwide. Founded in 1856, the company's corporate headquarters are situated in Watford, United Kingdom.
Show more...
執行長
Dr. Deepak S. Nath Ph.D.
員工
17349
國家
美國
ISIN
US83175M2052

上市

0 Comments

分享你的想法

FAQ

Smith & Nephew 今天的股價是多少?
SNN 目前價格為 $30.46 USD,過去 24 小時下跌了 -0.36%。在圖表上更密切關注 Smith & Nephew 股票的表現。
Smith & Nephew 的股票代號是什麼?
根據交易所不同,股票代號可能會有所差異。例如,在 交易所,Smith & Nephew 的股票以代號 SNN 進行交易。
Smith & Nephew 的股價在上漲嗎?
SNN 股票較上週上漲 +0.4%,本月上漲 +3.11%,過去一年 Smith & Nephew 上漲 +3.64%。
Smith & Nephew 下一次財報日期是什麼時候?
Smith & Nephew 將於 August 04, 2026 公布下一次財報。
Smith & Nephew 上一季度的財報如何?
SNN 上一季度的財報為每股 0.59 USD,預估為 0.58 USD,帶來 +2.16% 的驚喜。下一季度的預估財報為每股 不適用 USD。
Smith & Nephew 去年的營收是多少?
Smith & Nephew 去年的營收為 5.81BUSD。
Smith & Nephew 去年的淨利是多少?
SNN 去年的淨收益為 412MUSD。
Smith & Nephew 會發放股息嗎?
是的,SNN 的股息每 半年一次 發放一次。每股最新股息為 0.48 USD。截至今日,股息殖利率(FWD)% 為 2.57%。
Smith & Nephew 有多少名員工?
截至 June 15, 2026,公司共有 17,349 名員工。
Smith & Nephew 位於哪個產業?
Smith & Nephew從事於Health & Wellness產業。
Smith & Nephew 何時完成拆股?
Smith & Nephew 上次拆股發生於 October 15, 2014,比例為 2.5:1。
Smith & Nephew 的總部在哪裡?
Smith & Nephew 的總部位於 美國 的 Watford。